LRRN1 Inhibitors
LRRN1 Inhibitors are a diverse set of chemical compounds that impede the functional activity of LRRN1 through various signaling pathways. Compounds such as PD 98059, U0126, and SB 203580 target the MAPK/ERK and p38 MAPK pathways, crucial for neuronal development, and are known to influence the expression and function of LRRN1. The PI3K/Akt pathway inhibitors LY 294002 and Wortmannin, and the mTOR inhibitor Rapamycin, are also critical in diminishing the signals that regulate cell growth, proliferation, and differentiation where LRRN1 is actively involved. Furthermore, SP600125's inhibition of the JNK pathway, which is associated with neuronal plasticity, may also lead to the downregulation of LRRN1's role in brain development. BML-275, through its inhibition of the BMP pathway, and cyclopamine, as a Hedgehog pathway inhibitor, both have the potential to indirectly suppress LRRN1's activityin developmental processes by interfering with signaling pathways that LRRN1 is likely to intersect.
Gallotannin, in regulated amounts, can lead to excitotoxicity and impact neuronal survival, potentially affecting LRRN1's neurodevelopmental functions. Similarly, NF449's inhibition of G-protein signaling and Y-27632's interference with the ROCK pathway and subsequent actin cytoskeleton organization present additional mechanisms by which LRRN1 signaling may be indirectly lessened, given LRRN1's involvement in cell adhesion and neurite outgrowth. The collective action of these inhibitors, targeting different aspects of cellular signaling and development, contribute to the diminished functional activity of LRRN1. By inhibiting key pathways such as MAPK/ERK, PI3K/Akt, BMP, and Hedgehog, these compounds affect the cellular context in which LRRN1 operates, leading to an overall decrease in its activity without directly altering its expression or translation.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD 98059 is a MEK inhibitor that blocks the MAPK/ERK pathway. LRRN1 expression is modulated by ERK signaling, thus inhibition of this pathway by PD 98059 can lead to diminished LRRN1 signaling. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY 294002 is a PI3K inhibitor that disrupts the PI3K/Akt pathway. By decreasing PI3K activity, LY 294002 indirectly reduces LRRN1 activity as PI3K signaling is necessary for full LRRN1-mediated cell adhesion. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB 203580 is a p38 MAPK inhibitor that diminishes the response of cells to stress stimuli. Since LRRN1 is involved in neuronal development and its expression can be stress-regulated, SB 203580 indirectly lessens LRRN1 signaling by inhibiting p38 MAPK. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126, a MEK1/2 inhibitor, hinders the MAPK/ERK pathway, which is important in regulating neuronal differentiation. By inhibiting MEK1/2, U0126 can decrease the functional activity of LRRN1 in neuronal development. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is an irreversible PI3K inhibitor that suppresses the PI3K/Akt signaling cascade. This action indirectly diminishes LRRN1 activity as it is part of the signaling processes governed by PI3K. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor that attenuates the JNK signaling pathway. As JNK pathway influences neuronal plasticity and LRRN1 is implicated in brain development, inhibition by SP600125 may lead to decreased LRRN1 function. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor that lessens cell growth and proliferation signals. Since LRRN1 is associated with these processes in neurons, rapamycin may indirectly lead to reduced LRRN1 activity. | ||||||
BML-275 | 866405-64-3 | sc-200689 sc-200689A | 5 mg 25 mg | $94.00 $348.00 | 69 | |
BML-275 is an AMPK inhibitor that also inhibits the BMP pathway. Given that LRRN1 is involved in differentiation and development, inhibition of BMP signaling by BML-275 can result in diminished LRRN1 activity. | ||||||
Gallotannin | 1401-55-4 | sc-202619 sc-202619A sc-202619B sc-202619C sc-202619D sc-202619E sc-202619F | 1 g 10 g 100 g 250 g 1 kg 2.5 kg 5 kg | $25.00 $36.00 $66.00 $76.00 $229.00 $525.00 $964.00 | 12 | |
Gallotannin is a major excitatory neurotransmitter that can overactivate NMDA receptors, leading to excitotoxicity. Its regulated application can decrease neuronal survival, potentially affecting LRRN1's role in neurodevelopment. | ||||||
Cyclopamine | 4449-51-8 | sc-200929 sc-200929A | 1 mg 5 mg | $92.00 $204.00 | 19 | |
Cyclopamine is a Hedgehog signaling pathway inhibitor that can affect various developmental processes. As LRRN1 is implicated in neuronal development, cyclopamine may indirectly reduce LRRN1's functional activity in this context. | ||||||